Literature for PL-100 (A02.001 inhibitor)

(Topics flags: I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

2013
1. Asahchop,E.L., Oliveira,M., Quashie,P.K., Moisi,D., Martinez-Cajas,J.L., Brenner,B.G., Tremblay,C.L. and Wainberg,M.A.
   In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor
   J Antimicrob Chemother68, 105-112. PubMed  Europe PubMed DOI  I
2010
2. Jones,K.L., Holloway,M.K., Su,H.P., Carroll,S.S., Burlein,C., Touch,S., Distefano,D.J., Sanchez,R.I., Williams,T.M., Vacca,J.P. and Coburn,C.A.
   Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors
   Bioorg Med Chem Lett20, 4065-4068. PubMed  Europe PubMed DOI  I
2008
3. Dandache,S., Coburn,C.A., Oliveira,M., Allison,T.J., Holloway,M.K., Wu,J.J., Stranix,B.R., Panchal,C., Wainberg,M.A. and Vacca,J.P.
   PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study
   J Med Virol80, 2053-2063. PubMed  Europe PubMed DOI  I
4. Gulnik,S.V. and Eissenstat,M.
   Approaches to the design of HIV protease inhibitors with improved resistance profiles
   Curr Opin HIV AIDS3, 633-641. PubMed  Europe PubMed DOI  V  I
2007
5. Dandache,S., Sevigny,G., Yelle,J., Stranix,B.R., Parkin,N., Schapiro,J.M., Wainberg,M.A. and Wu,J.J.
   In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
   Antimicrob Agents Chemother51, 4036-4043. PubMed  Europe PubMed DOI  I
2006
6. [YEAR:24-4-2006]Stranix,B.R., Lavallee,J.F., Sevigny,G., Yelle,J., Perron,V., LeBerre,N., Herbart,D. and Wu,J.J.
   Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids
   Bioorg Med Chem Lett16, 3459-3462. PubMed  Europe PubMed DOI  I